HK1060135A1 - 4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds - Google Patents

4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Info

Publication number
HK1060135A1
HK1060135A1 HK04102956A HK04102956A HK1060135A1 HK 1060135 A1 HK1060135 A1 HK 1060135A1 HK 04102956 A HK04102956 A HK 04102956A HK 04102956 A HK04102956 A HK 04102956A HK 1060135 A1 HK1060135 A1 HK 1060135A1
Authority
HK
Hong Kong
Prior art keywords
compounds
production
pharmaceutical compositions
compositions containing
halogenated
Prior art date
Application number
HK04102956A
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Gunter Kaufmann
Hans-Udo Schweikert
Gerd Muller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HK1060135A1 publication Critical patent/HK1060135A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as inhibitors of the 5 alpha -reductase and, at the same time, as gestagens. Said compounds are thus suited for treating medical disorders that, in men and women, are a result of an increased androgen level in certain organs and tissues. The inventive compounds combined with other hormonal substances such as estrogen, testosterone or a potent androgen are suited as contraceptives for women and men.
HK04102956A 2000-09-04 2004-04-27 4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds HK1060135A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (en) 2000-09-04 2000-09-04 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
PCT/EP2001/009943 WO2002019971A1 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
HK1060135A1 true HK1060135A1 (en) 2004-07-30

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04102956A HK1060135A1 (en) 2000-09-04 2004-04-27 4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Country Status (29)

Country Link
EP (1) EP1423407B1 (en)
JP (1) JP2004513084A (en)
KR (1) KR100530816B1 (en)
CN (1) CN1262560C (en)
AT (1) ATE319733T1 (en)
AU (2) AU1047002A (en)
BG (1) BG107594A (en)
BR (1) BR0113618A (en)
CA (1) CA2421302C (en)
DE (2) DE10043846A1 (en)
DK (1) DK1423407T3 (en)
EA (1) EA006387B1 (en)
EE (1) EE05186B1 (en)
ES (1) ES2260294T3 (en)
HK (1) HK1060135A1 (en)
HR (1) HRP20030256A2 (en)
HU (1) HUP0300936A3 (en)
IL (2) IL154666A0 (en)
ME (1) MEP14408A (en)
MX (1) MXPA03001912A (en)
NO (1) NO325012B1 (en)
NZ (1) NZ524485A (en)
PL (1) PL360669A1 (en)
PT (1) PT1423407E (en)
RS (1) RS50305B (en)
SK (1) SK286757B6 (en)
UA (1) UA74592C2 (en)
WO (1) WO2002019971A1 (en)
ZA (1) ZA200301715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (en) 2001-08-28 2003-03-20 Jenapharm Gmbh New 17-methylene-4-azasteroids
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
DE202007019049U1 (en) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Use of a gestagen in combination with an estrogen for the prophylaxis of lactose intolerance in oral contraception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
EP1409512A1 (en) * 2000-06-27 2004-04-21 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
CA2421302C (en) 2007-08-14
PL360669A1 (en) 2004-09-20
EP1423407A1 (en) 2004-06-02
WO2002019971A9 (en) 2002-08-08
HUP0300936A2 (en) 2003-11-28
ZA200301715B (en) 2004-08-13
NO325012B1 (en) 2008-01-14
ES2260294T3 (en) 2006-11-01
SK286757B6 (en) 2009-05-07
EA200300322A1 (en) 2003-10-30
EP1423407B1 (en) 2006-03-08
PT1423407E (en) 2006-07-31
HRP20030256A2 (en) 2005-10-31
IL154666A0 (en) 2003-09-17
EE05186B1 (en) 2009-06-15
NO20030989L (en) 2003-05-02
UA74592C2 (en) 2006-01-16
IL154666A (en) 2008-12-29
AU2002210470B2 (en) 2006-07-20
HUP0300936A3 (en) 2010-01-28
JP2004513084A (en) 2004-04-30
WO2002019971A1 (en) 2002-03-14
RS50305B (en) 2009-09-08
BR0113618A (en) 2003-07-15
KR20030028836A (en) 2003-04-10
KR100530816B1 (en) 2005-11-25
DE50109175D1 (en) 2006-05-04
NO20030989D0 (en) 2003-03-03
SK2442003A3 (en) 2003-08-05
YU16403A (en) 2006-05-25
DE10043846A1 (en) 2002-04-04
EE200300087A (en) 2005-02-15
ATE319733T1 (en) 2006-03-15
AU1047002A (en) 2002-03-22
NZ524485A (en) 2005-11-25
BG107594A (en) 2003-09-30
MXPA03001912A (en) 2004-07-08
EA006387B1 (en) 2005-12-29
MEP14408A (en) 2010-06-10
CA2421302A1 (en) 2003-03-03
CN1452628A (en) 2003-10-29
CN1262560C (en) 2006-07-05
DK1423407T3 (en) 2006-07-03

Similar Documents

Publication Publication Date Title
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
ZA200203439B (en) Novel tropical oestroprogestational compositions with systemic effect.
HUP0102483A2 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
MEP38008A (en) Drospirenone for hormone replacement therapy
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
DE60115274D1 (en) USE OF ANTIPROGESTINES FOR PROPHYLAXIS AND TREATMENT OF HORMONE-RELATED DISEASES
SG154323A1 (en) Estrogen replacement therapy
IL125821A0 (en) A pharmaceutical composition containing dehydroepiandrosterone and aromatase inhibitors and use thereof
HK1060135A1 (en) 4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
MXPA05008347A (en) Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis.
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
AR032371A1 (en) USE OF ANTIPROGESTINES FOR PROFILAXIS AND TREATMENT OF HORMONE DEPENDENT DISEASES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100829